Distinct functional and molecular profiles between physiological and pathological atrial enlargement offer potential new therapeutic opportunities for atrial fibrillation
Clinical Science · 2024
DOI: 10.1042/cs20240178 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Science, 2024. Verfasst von Yi Ching Chen und 13 weiteren Autor:innen. Beteiligte Einrichtung: Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Atrial Fibrillation, Heart Atria, Mice, Transgenic, Myocytes, Cardiac. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council (NHMRC), Wellcome Trust, National Heart Foundation of Australia (Heart Foundation).
Abstract (Originalsprache)
Atrial fibrillation (AF) remains challenging to prevent and treat. A key feature of AF is atrial enlargement. However, not all atrial enlargement progresses to AF. Atrial enlargement in response to physiological stimuli such as exercise is typically benign and reversible. Understanding the differences in atrial function and molecular profile underpinning pathological and physiological atrial remodelling will be critical for identifying new strategies for AF. The discovery of molecular mechanisms responsible for pathological and physiological ventricular hypertrophy has uncovered new drug targets for heart failure. Studies in the atria have been limited in comparison. Here, we characterised mouse atria from (1) a pathological model (cardiomyocyte-specific transgenic (Tg) that develops dilated cardiomyopathy [DCM] and AF due to reduced protective signalling [PI3K]; DCM-dnPI3K), and (2) a physiological model (cardiomyocyte-specific Tg with an enlarged heart due to increased insulin-like growth factor 1 receptor; IGF1R). Both models presented with an increase in atrial mass, but displayed distinct functional, cellular, histological and molecular phenotypes. Atrial enlargement in the DCM-dnPI3K Tg, but not IGF1R Tg, was associated with atrial dysfunction, fibrosis and a heart failure gene expression pattern. Atrial proteomics identified protein networks related to cardiac contractility, sarcomere assembly, metabolism, mitochondria, and extracellular matrix which were differentially regulated in the models; many co-identified in atrial proteomics data sets from human AF. In summary, physiological and pathological atrial enlargement are associated with distinct features, and the proteomic dataset provides a resource to study potential new regulators of atrial biology and function, drug targets and biomarkers for AF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.
- Department of Diabetes, Central Clinical School, Monash University, Clayton, Victoria, Australia.
- Baker Department of Cardiometabolic Health, The University of Melbourne, Melbourne, Victoria, Australia.
- Baker Department of Cardiovascular Research, Translation and Implementation, La Trobe University, Melbourne, Victoria, Australia.
- Department of Cell Biology and Molecular Medicine, Rutgers New Jersey Medical School, NJ, U.S.A.
- Department of Anatomy and Physiology, University of Melbourne, Melbourne, Victoria, Australia.
ORCID-Profile: Yi Ching Chen, Julie R McMullen
Förderung
- National Health and Medical Research Council (NHMRC)
- Wellcome Trust
- National Heart Foundation of Australia (Heart Foundation)
Zitieren
APA
Chen, Y. C., Wijekoon, S., Matsumoto, A., Luo, J., Kiriazis, H., Masterman, E., Yildiz, G., Cross, J., Parslow, A. C., Chooi, R., Sadoshima, J., Greening, D. W., Weeks, K. L., & McMullen, J. R. (2024). Distinct functional and molecular profiles between physiological and pathological atrial enlargement offer potential new therapeutic opportunities for atrial fibrillation. Clinical Science. https://doi.org/10.1042/cs20240178
Vancouver
Chen YC, Wijekoon S, Matsumoto A, Luo J, Kiriazis H, Masterman E, et al. Distinct functional and molecular profiles between physiological and pathological atrial enlargement offer potential new therapeutic opportunities for atrial fibrillation. Clinical Science. 2024. doi:10.1042/cs20240178
BibTeX
@article{Chen2024,
author = {Chen, Yi Ching and Wijekoon, Seka and Matsumoto, Aya and Luo, Jieting and Kiriazis, Helen and Masterman, Emma and Yildiz, Gunes and Cross, Jonathon and Parslow, Adam C and Chooi, Roger and Sadoshima, Junichi and Greening, David W and Weeks, Kate L and McMullen, Julie R},
title = {Distinct functional and molecular profiles between physiological and pathological atrial enlargement offer potential new therapeutic opportunities for atrial fibrillation},
journal = {Clinical Science},
year = {2024},
doi = {10.1042/cs20240178}
}
EUVIMED